alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 13.2



CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350



In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2022 (the “Report”) by Siyata Mobile Inc. (the “Company”),
the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge:



| | (1) | the Report fully complies with the requirements of Section
13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
| | --- | -----------------------------------------------------------------------------------------------------------------------------



| | (2) | the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|Date: May 15, 2023 | /s/ Gerald Bernstein   
|------------------ | -----------------------
|                   | Gerald Bernstein       
|                   | Chief Financial Officer
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Small Business Administration

          - [Disaster Declaration # 12034 and # 12035]

# AGENCY:

U.S. Small Business Administration.

# ACTION:

Amendment 1.

# SUMMARY:

This is an amendment of the Presidential declaration of a major disaster for Public Assistance Only for the State of Arkansas (FEMA-1872-DR), dated 02/04/2010.

*Incident:*                         Severe Storms and Flooding.                    

*Incident Period:*                         12/23/2009 through 01/02/2010.                    

# Effective Date:

02/26/2010.

*Physical Loan Application Deadline Date:*                         04/05/2010.                    

*Economic Injury (EIDL) Loan Application Deadline Date:*                         11/04/2010.                    

# ADDRESSES:

Submit completed loan applications to: U.S. Small Business Administration, Processing and Disbursement Center, 14925 Kingsport Road, Fort Worth, TX 76155.

# FOR FURTHER INFORMATION CONTACT:

A. Escobar, Office of Disaster Assistance, U.S. Small Business Administration, 409 3rd Street, SW., Suite 6050, Washington, DC 20416.

# SUPPLEMENTARY INFORMATION:

The notice of the President's major disaster declaration for Private Non-Profit organizations in the State of Arkansas, dated 02/04/2010, is hereby amended to include the following areas as adversely affected by the disaster.

*Primary Counties:*                     Pulaski                

All other information in the original declaration remains unchanged.

(Catalog of Federal Domestic Assistance Numbers 59002 and 59008)

James E. Rivera,

Associate Administrator for Disaster Assistance.

[FR Doc. 2010-4936 Filed 3-8-10; 8:45 am]

BILLING CODE 8025-01-P
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   12-Mos
<FISCAL-YEAR-END>                               DEC-31-1999
<PERIOD-START>                                  JAN-01-1998
<PERIOD-END>                                    DEC-31-1999
<CASH>                                            3,807,368
<SECURITIES>                                              0
<RECEIVABLES>                                     1,023,054
<ALLOWANCES>                                              0
<INVENTORY>                                               0
<CURRENT-ASSETS>                                  5,071,912
<PP&E>                                            1,513,771
<DEPRECIATION>                                      893,926
<TOTAL-ASSETS>                                   20,184,893
<CURRENT-LIABILITIES>                             2,323,199
<BONDS>                                                   0
<PREFERRED-MANDATORY>                                     0
<PREFERRED>                                               0
<COMMON>                                             16,306
<OTHER-SE>                                       17,789,674
<TOTAL-LIABILITY-AND-EQUITY>                     20,184,893
<SALES>                                                   0
<TOTAL-REVENUES>                                  1,041,815
<CGS>                                                     0
<TOTAL-COSTS>                                       649,374
<OTHER-EXPENSES>                                  8,782,016
<LOSS-PROVISION>                                          0
<INTEREST-EXPENSE>                                  225,870
<INCOME-PRETAX>                                  (8,720,098)
<INCOME-TAX>                                         18,383
<INCOME-CONTINUING>                              (8,738,481)
<DISCONTINUED>                                            0
<EXTRAORDINARY>                                           0
<CHANGES>                                                 0
<NET-INCOME>                                     (8,738,481)
<EPS-BASIC>                                           (0.75)
<EPS-DILUTED>                                         (0.75)



</TABLE>
# C_2014253EN.01003201.xml

| 4.8.2014 | EN | Official Journal of the European Union | C 253/32 |
| --- | --- | --- | --- |

4.8.2014

EN

Official Journal of the European Union

C 253/32

---

Action brought on 23 April 2014 — Giuntoli/OHIM — Société des produits Nestlé (CREMERIA TOSCANA)

(Case T-256/14)

2014/C 253/46

Language in which the application was lodged: English

Parties

Parties

Applicant: Andrea Giuntoli (Barcelona, Spain) (represented by: A. Canela Giménez, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Société des produits Nestlé SA (Vevey, Switzerland)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 12 February 2014 given in Case R 886/2013-2; |
| --- | --- |

—

Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 12 February 2014 given in Case R 886/2013-2;

| — | Order OHIM and those who oppose this request to pay the costs. |
| --- | --- |

—

Order OHIM and those who oppose this request to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: The applicant

Applicant for a Community trade mark:

Community trade mark concerned: The figurative mark containing the verbal elements ‘CREMERIA TOSCANA’ for goods and services in the Classes 30, 35 and 43 — Community trade mark application No 9 5 49  346

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: Société des produits Nestlé SA

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: International trade mark registration of the figurative mark containing the verbal element ‘la Cremeria’

Mark or sign cited in opposition:

Decision of the Opposition Division: Upheld the opposition in part

Decision of the Opposition Division:

Decision of the Board of Appeal: Annulled the appealed decision, accepted the opposition and partially rejected the CTM application.

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) of Regulation No 207/2009.

Pleas in law:

---
Exhibit 99(b)


        Written Statement of the Vice President Law/Finance and Secretary
                          Pursuant to 18 U.S.C. ss.1350


     Solely for the purposes of complying with 18 U.S.C. ss.1350, I, the
undersigned Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
"Company"), hereby certify, based on my knowledge, that the Quarterly Report on
Form 10-Q/A of the Company for the quarter ended June 30, 2002 (the "Report")
fully complies with the requirements of Section 13(a) of the Securities Exchange
Act of 1934, and that information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the
Company.




/s/  Wayne E. Larsen
------------------------------------
Wayne E. Larsen
October 31, 2002
<PAGE>   1

                                                                    EXHIBIT 23.5

                   CONSENT OF KPMG LLP, INDEPENDENT AUDITORS

The Board of Directors
Ribi ImmunoChem Research, Inc.:

We consent to the incorporation by reference of our report dated January 22,
1999, with respect to the balance sheets of Ribi ImmunoChem Research, Inc. as of
December 31, 1998 and 1997, and the related statements of operations,
stockholders' equity and comprehensive income, and cash flows for each of the
years in the three-year period ended December 31, 1998, which report appears in
the Form S-8 of Corixa Corporation dated October 21, 1999 related to the
following Anergen, Inc. benefit plans: 1998 Stock Option Plan, 1992 Consultant
Plan, 1995 Director Option Plan, and the 1996 Stock Option Plan.


KPMG LLP

Billings, Montana
October 21, 1999
ex10-10.htm


	
			

				Exhibit 10.10



                                   


Description of Director Compensation


 


Directors who are employees of YuMe, Inc. (“YuMe”) do not receive compensation from YuMe for the services they provide as directors. Each non-employee director will be eligible to receive compensation for his or her service consisting of annual cash retainers and equity awards as follows:


 


	
			Position

				
			 

				
			Retainer

				
			 

			
	
			Board Member

				
			 

				
			$

				
			30,000

				
			 

			
	
			Lead Independent Director

				
			 

				
			 

				
			15,000

				
			 

			
	
			Audit Committee Chair

				
			 

				
			 

				
			20,000

				
			 

			
	
			Compensation Committee Chair

				
			 

				
			 

				
			15,000

				
			 

			
	
			Nominating and Corporate Governance Committee Chair

				
			 

				
			 

				
			7,500

				
			 

			
	
			Audit Committee Member

				
			 

				
			 

				
			7,500

				
			 

			
	
			Compensation Committee Member

				
			 

				
			 

				
			7,500

				
			 

			
	
			Nominating and Corporate Governance Committee Member

				
			 

				
			 

				
			3,500

				
			 

			



 


Each of the above-mentioned cash retainers will be paid in four quarterly installments. Non-employee directors are also reimbursed for customary travel expenses incurred attending Company meetings and for continuing education opportunities. The Company does not pay, and its directors do not receive, any “per-meeting” fees.


 


For 2017, equity awards will consist of an initial stock option or restricted stock unit grant, upon first appointment to our board of directors, with a Black-Scholes value of $87,500. There are no annual refresh awards granted to existing non-employee directors. Options will be granted with an exercise price equal to the fair market value of YuMe’s common stock on the date of grant and vest annually over three years after the grant date for initial grants. Restricted stock awards will be granted with a fair market value equal to the closing price of YuMe’s common stock on the date of grant and vest over three years after the grant date for initial grants.
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.5820 Implanted cerebellar stimulator. ( a ) *Identification.* An implanted cerebellar stimulator is a device used to stimulate electrically a patient's cerebellar cortex for the treatment of intractable epilepsy, spasticity, and some movement disorders. The stimulator consists of an implanted receiver with electrodes that are placed on the patient's cerebellum and an external transmitter for transmitting the stimulating pulses across the patient's skin to the implanted receiver.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date premarket approval application (PMA) or notice of completion of a product development protocol (PDP) is required.* A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before September 26, 1984. Any implanted cerebellar stimulator that was not in commercial distribution before May 28, 1976, or that has not on or before September 26, 1984 been found by FDA to be substantially equivalent to an implanted cerebellar stimulator that was in commercial distribution before May 28, 1976 shall have an approved PMA or declared completed PDP in effect before beginning commercial distribution.
[44 FR 51730, Sept. 4, 1979, as amended at 49 FR 26574, June 28, 1984]
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 385 Engrossed in House (EH)]

<DOC>
H. Res. 385

                In the House of Representatives, U. S.,

                                                         June 15, 2017.
Whereas on June 14, 2017, an armed gunman opened fire at a practice for the 
        annual Congressional Baseball Game for Charity, wounding five 
        individuals;
Whereas United States Capitol Police Special Agents Crystal Griner, David 
        Bailey, and Henry Cabrera responded decisively to the attack, risking 
        their own lives to save the lives of others;
Whereas Special Agent Griner, who has been a member of the Capitol Police since 
        July 2008, was wounded in the course of confronting and subduing the 
        attacker;
Whereas Special Agent Bailey, who has been a member of the Capitol Police since 
        April 2008, was wounded in the course of confronting and subduing the 
        attacker;
Whereas Matthew (Matt) Mika, who was formerly a legislative aide for 
        Representative Nick Smith, Representative Dave Camp, and Representative 
        Tim Walberg, was wounded in the attack;
Whereas Zachary (Zack) Barth, a legislative aide to Representative Roger 
        Williams, was injured in the attack; and
Whereas Representative Steve Scalise, who has served the first congressional 
        district of Louisiana since 2008, husband of Jennifer Scalise and father 
        to Madison and Harrison, was wounded in the attack: Now, therefore, be 
        it
    Resolved, That the House of Representatives--
            (1) expresses its deep gratitude to United States Capitol Police 
        Special Agents Griner, Bailey, and Cabrera who bravely placed themselves 
        in harm's way to protect and save the lives of scores of individuals;
            (2) expresses its appreciation for the daily courage and dedication 
        of the United States Capitol Police who protect the Capitol grounds, 
        Members of Congress, and the public, to whom the Capitol belongs;
            (3) expresses its thanks to the Alexandria Police Department, 
        Alexandria Sheriff's Office, and Alexandria Fire Department for 
        responding swiftly and effectively to aid the United States Capitol 
        Police officers on the scene;
            (4) expresses its thanks to the first responders and health care 
        professionals who tended to the victims;
            (5) expresses its hope for a speedy and full recovery for the 
        injured;
            (6) reaffirms that an attack on any Member of Congress is an attack 
        on every Member, on the institution, and on the very principle of 
        representative democracy; and
            (7) stands firm in its belief that violence has no place in a 
        pluralistic society where differences are settled through debate, 
        ballots, and a legislative process, which rests at the bedrock of our 
        representative democracy.
            Attest:

                                                                          Clerk.
```
EXHIBIT 23.4

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the use in this Registration  Statement on Form S-4 of PSEG
Energy Holdings Inc. of our report dated March 3, 2000 relating to the financial
statements  of GWF Power  Systems,  L.P.,  which  appears  in such  Registration
Statement. We also consent to the reference to us under the heading "Experts" in
such Registration Statement.

San Francisco, California                         /s/ PricewaterhouseCoopers LLP
July 10, 2000
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.2300 Colorimeter, photometer, or spectrophotometer for clinical use. ( a ) *Identification.* A colorimeter, a photometer, or a spectrophotometer for clinical use is an instrument intended to measure radiant energy emitted, transmitted, absorbed, or reflected under controlled conditions. The device may include a monochromator to produce light of a specific wavelength.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2309, Jan. 14, 2000]
# Tower

# Creek

# Misc
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2370 Electrocardiograph surface electrode tester. ( a ) *Identification.* An electrocardiograph surface electrode tester is a device used to test the function and application of electrocardiograph electrodes.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 341
Editorial Note: Nomenclature changes to part 341 appear at 69 FR 13717, Mar. 24, 2004.

§ 341.20 Nasal decongestant active ingredients. The active ingredient of the product consists of any of the following when used within the dosage limits and in the dosage forms established for each ingredient: ( a ) *Oral nasal decongestants.* ( 1 ) Phenylephrine hydrochloride.
( 2 ) Pseudoephedrine hydrochloride.
( 3 ) Pseudoephedrine sulfate.
( 4 ) Phenylephrine bitartrate in an effervescent dosage form.
( b ) *Topical nasal decongestants.* ( 1 ) Levmetamfetamine.
( 2 ) Ephedrine.
( 3 ) Ephedrine hydrochloride.
( 4 ) Ephedrine sulfate.
( 5 ) [Reserved]
( 6 ) Naphazoline hydrochloride.
( 7 ) Oxymetazoline hydrochloride.
( 8 ) Phenylephrine hydrochloride.
( 9 ) Propylhexedrine.
( 10 ) Xylometazoline hydrochloride.
[59 FR 43409, Aug. 23, 1994, as amended at 63 FR 40650, July 30, 1998; 71 FR 43362, Aug. 1, 2006]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1220 Electrode recording catheter or electrode recording probe. ( a ) *Identification.* An electrode recording catheter or an electrode recording probe is a device used to detect an intracardiac electrocardiogram, or to detect cardiac output or left-to-right heart shunts. The device may be unipolar or multipolar for electrocardiogram detection, or may be a platinum-tipped catheter which senses the presence of a special indicator for cardiac output or left-to-right heart shunt determinations.
( b ) *Classification.* Class II (performance standards).
§ 861.1 Purpose and scope. ( a ) This part implements section 514 of the Federal Food, Drug, and Cosmetic Act (the act) with respect to the establishment, amendment, and revocation of performance standards applicable to devices intended for human use.
( b ) The Food and Drug Administration may determine that a performance standard, as described under special controls for class II devices in § 860.7(b) of this chapter, is necessary to provide reasonable assurance of the safety and effectiveness of the device. Performance standards may be established for: ( 1 ) A class II device;
( 2 ) A class III device which, upon the effective date of the standard, is reclassified into class II; and
( 3 ) A class III device, as a condition to premarket approval under section 515 of the act, to reduce or eliminate a risk or risks associated with such device.
( c ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.
[45 FR 7484, Feb. 1, 1980, as amended at 45 FR 23686, Apr. 8, 1980; 57 FR 58404, Dec. 10, 1992]
§ 876.5020 External penile rigidity devices. ( a ) *Identification.* External penile rigidity devices are devices intended to create or maintain sufficient penile rigidity for sexual intercourse. External penile rigidity devices include vacuum pumps, constriction rings, and penile splints which are mechanical, powered, or pneumatic devices.
( b ) *Classification.* Class II (special controls). The devices are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9. The special control for these devices is the FDA guidance document entitled “Class II Special Controls Guidance Document: External Penile Rigidity Devices.” See § 876.1(e) for the availability of this guidance document.
[69 FR 77623, Dec. 28, 2004]